Clinical Trial Update: A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/2 trial evaluating PLX3397 with radiation therapy and temozolomide in newly diagnosed glioblastoma has completed; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• PLX3397 (PLX3397)
• Radiation therapy
• Temozolomide (Temozolomide)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Patients With Newly Diagnosed Glioblastoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-10-09